David Chang, MD
Internal Medicine · Easley, SCNPI 1487638581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 908 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 908 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$1K
- Lilly USA, LLC$1K
- GSK$664
- plus $6K from 47 others
What the payments were for
- Food & beverage$13,00899%
- Education$1541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$13,162 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 254 | $283,573 |
| EliquisApixaban | 179 | $158,617 |
| JardianceEmpagliflozin | 152 | $127,411 |
| OzempicSemaglutide | 88 | $106,557 |
| RybelsusSemaglutide | 70 | $79,365 |
| XareltoRivaroxaban | 77 | $66,320 |
| Repatha SureclickEvolocumab | 74 | $66,251 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $57,959 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $50,315 |
| FarxigaDapagliflozin Propanediol | 61 | $48,800 |
| NexletolBempedoic Acid | 62 | $33,905 |
| Droxidopa | 12 | $33,231 |
| VraylarCariprazine Hcl | 21 | $31,383 |
| TrintellixVortioxetine Hydrobromide | 40 | $31,271 |
| MyrbetriqMirabegron | 36 | $30,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,058 | $307,058272 claims |
| Novo NordiskOzempic, Rybelsus | $1,602 | $185,921158 claims |
| PfizerEliquis | $1,088 | $158,617179 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $366 | $137,564170 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,258 | $78,325106 claims |
| AbbVieVraylar, Synthroid, Savella, Linzess | $1,518 | $77,640301 claims |
| Johnson & JohnsonXarelto | $401 | $66,32077 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $664 | $58,42484 claims |
| Esperion Therapeutics, Inc.Nexletol | $231 | $33,90562 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $374 | $31,27140 claims |
| Astellas Pharma US IncMyrbetriq | $264 | $30,73836 claims |
| BayerKerendia | $202 | $25,31934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Easley
- Roger BoatwrightEasley$13K
- Steven FreemanEasley$10K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.